Maybury, B, Cook, G, Pratt, G et al. (2 more authors) (2016) Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma. Biology of Blood and Marrow Transplantation, 22 (11). pp. 1926-1937. ISSN 1083-8791
Abstract
Consolidation with high-dose chemotherapy and autologous stem cell transplantation (ASCT) is the standard of care for transplantation-eligible patients with multiple myeloma, based on randomized trials showing improved progression-free survival with autologous transplantation after combination chemotherapy induction. These trials were performed before novel agents were introduced; subsequently, combinations of immunomodulatory drugs and proteasome inhibitors as induction therapy have significantly improved rates and depth of response. Ongoing randomized trials are testing whether conventional autologous transplantation continues to improve responses after novel agent induction. Although these results are awaited, it is important to review strategies for improving outcomes after ASCT. Conditioning before ASCT with higher doses of melphalan and combinations of melphalan with other agents, including radiopharmaceuticals, has been explored. Tandem ASCT, consolidation, and maintenance therapy after ASCT have been investigated in phase III trials. Experimental cellular therapies using ex vivo–primed dendritic cells, ex vivo–expanded autologous lymphocytes, Killer Immunoglobulin Receptor (KIR)-mismatched allogeneic natural killer cells, and genetically modified T cells to augment ASCT are also in phase I trials. This review summarizes these strategies and highlights the importance of exploring strategies to augment ASCT, even in the era of novel agent induction.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2016 American Society for Blood and Marrow Transplantation. This is an author produced version of a paper published in Biology of Blood and Marrow Transplantation. Uploaded in accordance with the publisher's self-archiving policy. |
Keywords: | Multiple myeloma; Stem cell transplantation; Conditioning; Immunotherapy; Minimal residual disease |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Oncology and Clinical Research (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 31 Jan 2017 10:50 |
Last Modified: | 08 Jun 2017 00:38 |
Published Version: | https://doi.org/10.1016/j.bbmt.2016.06.004 |
Status: | Published |
Publisher: | Elsevier |
Identification Number: | 10.1016/j.bbmt.2016.06.004 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:111336 |